SCHEMBL23701474

SCHEMBL23701474

CC12CN(C(=O)O)CC1(C)CN(c1ccc(N3CCN(S(C)(=O)=O)CC3)cc1)C2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
SMN1; SMN2 Q16637 6/20 0.50
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
RAB9A P51151 4/20 0.50
NPC1 O15118 3/20 0.50
POLB P06746 2/20 0.49
HIF1A Q16665 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 3/20 0.47
CYP2C19 P33261 3/20 0.47
HSD17B10 Q99714 2/20 0.47
USP2 O75604 1/20 0.47
KDM4E B2RXH2 3/20 0.45
LMNA P02545 1/20 0.44
THRB P10828 1/20 0.44
TSHR P16473 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701397 0.83 GAA (0.50) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL31055744 0.83 GPR119 (0.53) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23732385 0.83 GPR119 (0.53) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701395 0.83 GAA (0.50) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL22015092 0.81 HIF1A (0.50) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701368 0.81 GAA (0.46) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701371 0.81 GAA (0.46) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701439 0.78 MAPT (0.52) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL23701434 0.78 KDM4E (0.41) SMN1; SMN2MEN1KMT2ARAB9ANPC1
SCHEMBL23701437 0.78 KDM4E (0.55) MEN1KMT2ACYP1A2ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors LOX, LOXL1, LOXL3 MAPT 4829/4885SMN1; SMN2 3383/4885MEN1 4448/4885
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS LOX, LOXL1, LOXL3 MAPT 4829/4885SMN1; SMN2 3383/4885MEN1 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.